SHAREHOLDER ALERT: Scott + Scott, LLP Investigating PTC Therapeutics (PTCT) for Possible Securities Fraud

NEW YORK--()--Scott + Scott, Attorneys at Law, LLP has commenced an investigation of PTC Therapeutics, Inc. (PTCT) for possible securities law violations.

On February 23, 2016, PTC announced that it had received a Refuse to File letter from the United States Food and Drug Administration (the “FDA”) regarding PTC’s New Drug Application for the drug Translarna. The FDA stated in its Refuse to File letter that the application was not sufficiently complete to permit a substantive review. On this news, PTC has fallen more than 55% on intraday trading.

To obtain additional information, contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (216) 229-6088 or (212) 223-6444, toll-free (866) 326-5057 or by email at gjohnson@scott-scott.com or jhalloran@scott-scott.com.

Scott + Scott, Attorneys at Law, LLP has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio.

This release may be considered attorney advertising in some jurisdictions under the applicable laws and ethical rules. Prior results do not guarantee similar outcomes.

Contacts

Scott + Scott, Attorneys at Law, LLP
Geoffrey M. Johnson, (216) 229-6088, toll-free (866) 326-5057
gjohnson@scott-scott.com
or
Joseph Halloran, (212) 223-6444
jhalloran@scott-scott.com

Recent Stories

RSS feed for Scott + Scott, Attorneys at Law, LLP

Scott + Scott, Attorneys at Law, LLP